On September 19, 2023, it was announced that BTC Capital Management Inc. had acquired a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the second quarter. As per its recent disclosure with the Securities and Exchange Commission, the institutional investor purchased 20,282 shares of the biopharmaceutical company’s stock, with an approximate value of $275,000.
Catalyst Pharmaceuticals (NASDAQ:CPRX) recently released its quarterly earnings results on August 9th. The biopharmaceutical company reported earnings per share of $0.33 for the quarter, surpassing analysts’ consensus estimates by $0.08. The firm generated revenue of $99.58 million for the quarter, exceeding analyst expectations of $92.77 million. Furthermore, Catalyst Pharmaceuticals demonstrated a net margin of 38.14% and a return on equity of 36.13%. Based on forecasts made by sell-side analysts, it is anticipated that Catalyst Pharmaceuticals will post EPS of 0.87 for the current fiscal year.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company based in the United States, is primarily focused on developing and commercializing therapies for individuals suffering from rare debilitating chronic neuromuscular and neurological diseases. The company offers Firdapse, which consists of amifampridine phosphate tablets designed to treat patients with lambert-eaton myasthenic syndrome (LEMS). Additionally, Catalyst Pharmaceuticals provides Ruzurgi as a treatment option for pediatric LEMS patients.
This recent acquisition by BTC Capital Management Inc., along with Catalyst Pharmaceuticals’ strong financial performance and tailored approach to addressing rare neuromuscular and neurological diseases, showcases potential growth opportunities for the company in the biopharmaceutical sector moving forward.
Northrop Grumman Corporation
Updated on: 24/09/2023
Debt to equity ratio: Buy
Price to earnings ratio: Strong Buy
Price to book ratio: Strong Buy
DCF: Strong Buy
We did not find social sentiment data for this stock
|Analyst / firm||Rating|
Institutional Investors Show Increased Confidence in Catalyst Pharmaceuticals as Sentiment Shifts
In recent months, several large investors have made significant changes to their positions in Catalyst Pharmaceuticals, a biopharmaceutical company. These adjustments reflect the dynamic nature of the investment landscape and provide insight into the evolving sentiment surrounding the company.
One notable investor is Brookstone Capital Management, which has increased its holdings in Catalyst Pharmaceuticals by 10.3% during the second quarter. This increase translates to an additional 3,439 shares now owned by Brookstone Capital Management, valued at $455,000. It is worth noting that this boost in holdings demonstrates confidence in Catalyst Pharmaceuticals’ potential for growth and profitability.
Furthermore, Level Four Advisory Services LLC has entered the picture as a new investor in Catalyst Pharmaceuticals. During the first quarter, they purchased a stake valued at $177,000. This acquisition highlights Level Four Advisory Services LLC’s belief in Catalyst Pharmaceuticals’ ability to deliver positive returns on investment.
Capital Impact Advisors LLC also displayed interest in Catalyst Pharmaceuticals by increasing its holdings by 3.4% during the first quarter. With an additional 1,497 shares valued at $764,000 under their possession, Capital Impact Advisors LLC demonstrates a continued endorsement of the biopharmaceutical company’s prospects.
Additionally, Advisory Services Network LLC witnessed tremendous growth in their holdings of Catalyst Pharmaceuticals during the first quarter. Their holdings increased by 260.2%, adding an extra 1,301 shares valued at $30,000 to their portfolio.
Finally, Rockefeller Capital Management L.P.’s dedication to Catalyst Pharmaceuticals is evident through its remarkable increase in holdings. During the first quarter alone, Rockefeller Capital Management L.P. acquired an additional 15,707 shares worth $265,000—an astounding growth rate of 5,235.7%.
It is essential to note that hedge funds and other institutional investors currently own approximately 77.27% of Catalyst Pharmacuticals’ stock—further testament to its allure and potential as an investment opportunity.
On September 19, 2023, Catalyst Pharmaceuticals’ stock opened at $12.62. With a market capitalization of $1.35 billion, a moderate PE ratio of 12.50, and a beta of 1.11, the company’s financials appear stable and attractive to investors.
Over the past year, Catalyst Pharmaceuticals has experienced a range between $11.09 and $22.11, indicating some volatility in its share price. However, the stock has recently shown promising stability with a 50-day moving average price of $13.70 and a 200-day moving average price of $14.25.
Several research firms have issued reports on Catalyst Pharmaceuticals in recent times. Cantor Fitzgerald reaffirmed their “overweight” rating on the company’s shares with a target price of $27.00 on August 22nd. Likewise, HC Wainwright has maintained its “buy” rating with a target price of $24.00 since August 11th.
Piper Sandler increased their target price from $21.00 to $24.00 on June 21st, while Truist Financial did the same on June 20th. Finally, StockNews.com initiated coverage on Catalyst Pharmaceuticals with a “hold” rating for the company on August 17th.
Based on data from Bloomberg and various research reports, Catalyst Pharmaceuticals has received an average rating of “Moderate Buy.” Analysts have also provided a consensus target price for the stock at around $24.75.
These factors collectively suggest that Catalyst Pharmaceuticals remains an intriguing investment opportunity within the biopharmaceutical industry sector—a sentiment shared by numerous institutional investors and research firms alike.
(Note: This article is purely informational and should not be considered as financial advice.)